The Active Comparator (CNTO 1275/Enbrel) Psoriasis Trial (ACCEPT) was designed to compare the benefits and risks of etanercept and ustekinumab in patients with moderate-to-severe psoriasis.

A 20-year-old female presented with a history of psoriasis and psoriatic arthritis since childhood. She started treatment with etanercept (Enbrel ®) 1 month previously. One day after a ...